Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN1012 in Subjects with Unresectable or Metastatic Advanced Solid Tumors

NCT05580991 is registered in ClinicalTrials.gov with Canwell Biotech Limited as lead sponsor.

NCT NCT05580991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05580991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN1012 in Subjects with Unresectable or Metastatic Advanced Solid Tumors
Lead sponsor
Canwell Biotech Limited
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 9, 2022
Completion date
June 30, 2025
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor